87
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The role of TGF-β and its crosstalk with RAC1/RAC1b signaling in breast and pancreas carcinoma

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This article focusses on the role of TGF-β and its signaling crosstalk with the RHO family GTPases RAC1 and RAC1b in the progression of breast and pancreatic carcinoma. The aggressive nature of these tumor types is mainly due to metastatic dissemination. Metastasis is facilitated by desmoplasia, a peculiar tumor microenvironment and the ability of the tumor cells to undergo epithelial-mesenchymal transition (EMT) and to adopt a motile and invasive phenotype. These processes are controlled entirely or in part by TGF-β and the small RHO GTPase RAC1 with both proteins acting as tumor promoters in late-stage cancers. Data from our and other studies point to signaling crosstalk between TGF-β and RAC1 and the related isoform, RAC1b, in pancreatic and mammary carcinoma cells. Based on the exciting observation that RAC1b functions as an endogenous inhibitor of RAC1, we propose a model on how the relative abundance or activity of RAC1 and RAC1b in the tumor cells may determine their responses to TGF-β and, ultimately, the metastatic capacity of the tumor.

          Related collections

          Most cited references81

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Cancer metastases: challenges and opportunities

          Cancer metastasis is the major cause of cancer morbidity and mortality, and accounts for about 90% of cancer deaths. Although cancer survival rate has been significantly improved over the years, the improvement is primarily due to early diagnosis and cancer growth inhibition. Limited progress has been made in the treatment of cancer metastasis due to various factors. Current treatments for cancer metastasis are mainly chemotherapy and radiotherapy, though the new generation anti-cancer drugs (predominantly neutralizing antibodies for growth factors and small molecule kinase inhibitors) do have the effects on cancer metastasis in addition to their effects on cancer growth. Cancer metastasis begins with detachment of metastatic cells from the primary tumor, travel of the cells to different sites through blood/lymphatic vessels, settlement and growth of the cells at a distal site. During the process, metastatic cells go through detachment, migration, invasion and adhesion. These four essential, metastatic steps are inter-related and affected by multi-biochemical events and parameters. Additionally, it is known that tumor microenvironment (such as extracellular matrix structure, growth factors, chemokines, matrix metalloproteinases) plays a significant role in cancer metastasis. The biochemical events and parameters involved in the metastatic process and tumor microenvironment have been targeted or can be potential targets for metastasis prevention and inhibition. This review provides an overview of these metastasis essential steps, related biochemical factors, and targets for intervention.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression

            From the earliest stages of embryonic development, cells of epithelial and mesenchymal origin contribute to the structure and function of developing organs. However, these phenotypes are not always permanent, and instead, under the appropriate conditions, epithelial and mesenchymal cells convert between these two phenotypes. These processes, termed Epithelial-Mesenchymal Transition (EMT), or the reverse Mesenchymal-Epithelial Transition (MET), are required for complex body patterning and morphogenesis. In addition, epithelial plasticity and the acquisition of invasive properties without the full commitment to a mesenchymal phenotype are critical in development, particularly during branching morphogenesis in the mammary gland. Recent work in cancer has identified an analogous plasticity of cellular phenotypes whereby epithelial cancer cells acquire mesenchymal features that permit escape from the primary tumor. Because local invasion is thought to be a necessary first step in metastatic dissemination, EMT and epithelial plasticity are hypothesized to contribute to tumor progression. Similarities between developmental and oncogenic EMT have led to the identification of common contributing pathways, suggesting that the reactivation of developmental pathways in breast and other cancers contributes to tumor progression. For example, developmental EMT regulators including Snail/Slug, Twist, Six1, and Cripto, along with developmental signaling pathways including TGF-β and Wnt/β-catenin, are misexpressed in breast cancer and correlate with poor clinical outcomes. This review focuses on the parallels between epithelial plasticity/EMT in the mammary gland and other organs during development, and on a selection of developmental EMT regulators that are misexpressed specifically during breast cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.

              About 90 percent of human pancreatic carcinomas show allelic loss at chromosome 18q. To identify candidate tumor suppressor genes on 18q, a panel of pancreatic carcinomas were analyzed for convergent sites of homozygous deletion. Twenty-five of 84 tumors had homozygous deletions at 18q21.1, a site that excludes DCC (a candidate suppressor gene for colorectal cancer) and includes DPC4, a gene similar in sequence to a Drosophila melanogaster gene (Mad) implicated in a transforming growth factor-beta (TGF-beta)-like signaling pathway. Potentially inactivating mutations in DPC4 were identified in six of 27 pancreatic carcinomas that did not have homozygous deletions at 18q21.1. These results identify DPC4 as a candidate tumor suppressor gene whose inactivation may play a role in pancreatic and possibly other human cancers.
                Bookmark

                Author and article information

                Contributors
                melzer.catharina@mh-hannover.de
                hass.ralf@mh-hannover.de
                Ohe.Juliane.von.der@mh-hannover.de
                hendrik.lehnert@uni-luebeck.de
                +49-(0)451- 3101-7866 , hendrik.ungefroren@uksh.de
                Journal
                Cell Commun Signal
                Cell Commun. Signal
                Cell Communication and Signaling : CCS
                BioMed Central (London )
                1478-811X
                12 May 2017
                12 May 2017
                2017
                : 15
                : 19
                Affiliations
                [1 ]ISNI 0000 0000 9529 9877, GRID grid.10423.34, Biochemistry and Tumor Biology Lab, Department of Obstetrics and Gynecology, , Hannover Medical School, ; Hannover, Germany
                [2 ]ISNI 0000 0001 0057 2672, GRID grid.4562.5, , Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, ; Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
                [3 ]GRID grid.37828.36, First Department of Medicine, , University Hospital Schleswig-Holstein (UKSH), ; Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
                [4 ]ISNI 0000 0004 0646 2097, GRID grid.412468.d, Department of General and Thoracic Surgery, , UKSH, ; Campus Kiel, Kiel, Germany
                Author information
                http://orcid.org/0000-0002-7552-2087
                Article
                175
                10.1186/s12964-017-0175-0
                5429551
                28499439
                82410b0d-aa5a-4040-b0f3-d037e96e679b
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 20 March 2017
                : 8 May 2017
                Funding
                Funded by: Erich und Gertrud Roggenbuck-Stiftung for Cancer Research
                Categories
                Review
                Custom metadata
                © The Author(s) 2017

                Cell biology
                breast cancer,pancreas cancer,tumor cell signaling,tumor microenvironment,tgf-β,rac1,metastasis

                Comments

                Comment on this article